Moderna Inc is trading 4.1% down today at $45.64, underperforming as tech and growth stocks slide amid renewed higher-for-longer interest rate fears.
- The downward move comes despite yesterday's positive announcement regarding UK approval for a Lynch syndrome mRNA cancer vaccine trial in partnership with Oxford University.
- Broader market sentiment is sharply risk-off, and there are no clear company-specific negative headlines to offset the current volatility in the biotech sector.